The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B

  • Kim, Chang Wook (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kim, Chang Seop (Neane Clinic) ;
  • Kim, Hee Yeon (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Chang Don (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Yu, Kyungha (Bristol-Myers Squibb) ;
  • Llamoso, Cyril (Bristol-Myers Squibb, Wallingford) ;
  • Lee, Heon Ju (Department of Internal Medicine, Yeungnam University College of Medicine)
  • Received : 2016.04.04
  • Accepted : 2016.10.15
  • Published : 2018.01.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation in patient's number. A large-scale nation-wide real-world surveillance study was carried out to investigate safety, efficacy and clinical effectiveness of ETV in Korean patients with chronic hepatitis B (CHB). Methods: Between 2006 and 2012, 3,444 patients were enrolled from 132 Korean institutions. For the safety assessment, investigators recorded the occurrence of observed and patient-reported adverse events (AEs), as well as laboratory abnormalities. Efficacy, which consisted of change in HBV DNA and alanine aminotransferase (ALT), was evaluated in patients who had received at least 16 weeks of ETV treatment. Overall clinical effectiveness, based on improvement of ALT, HBV DNA and patient's symptoms, was evaluated by physicians. Results: Of the patients, 3,367 were evaluated for safety and 3,115 for efficacy and clinical effectiveness. Three hundred and eighty AEs were reported in 255 cases (7.57%), and 67 adverse drug reactions in 54 cases (1.6%). Serious AEs (SAE) were 19 events in nine cases (0.27%). Serious adverse drug reactions (SADR) were three events in two cases (0.06%), and unexpected SAE/SADR were three events in two cases (0.06%). Medical history and concomitant medications were factors inf luencing incidence rates of AEs. Overall clinical effectiveness rate was 96.53%, which was clinically assessed as marked improved or improved state. Conclusions: This study showed that ETV was well tolerated and clinically effective in Korean patients with CHB in a real-world nation-wide setting.

Keywords

References

  1. World Health Organization (WHO). Hepatitis B [Internet]. Geneva: WHO, c2017 [cited 2017 Sep 5]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
  2. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009;15 Suppl 6:S13-S24. https://doi.org/10.3350/kjhep.2009.15.S6.S13
  3. Korea Centers for Disease Control & Prevention. Korea National Health and Nutrition Examination Survey [Internet]. Cheongju (KR): Korea Centers for Disease Control & Prevention, c2012 [cited 2017 Sep 5]. Available from: http://knhanes.cdc.go.kr/knhanes/index.do.
  4. Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-820. https://doi.org/10.3346/jkms.2005.20.5.816
  5. Kim H, Jee YM, Song BC, et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007;50:52-57. https://doi.org/10.1159/000096313
  6. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-162. https://doi.org/10.3350/cmh.2012.18.2.109
  7. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012;19:377-386. https://doi.org/10.1111/j.1365-2893.2012.01602.x
  8. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. https://doi.org/10.1056/NEJMoa051285
  9. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020. https://doi.org/10.1056/NEJMoa051287
  10. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049. https://doi.org/10.1053/j.gastro.2006.04.007
  11. Bristol-Myers Squibb Company. Entecavir (BMS-200475): Antiviral Drugs Advisory Committee (AVDAC) briefing document [Internet]. Silver Spring (MD): Food and Drug Administration, 2005 [cited 2017 Sep 5]. Available from: https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4094B1_01_BristolMyersSquibb-entecavir.pdf.
  12. National Institutes of Health (NIH). Study of entecavir in patients with chronic hepatitis B virus infection [Internet]. Bethesda (MD): NIH, c2015 [cited 2017 Sep 5]. Available from: http://clinicaltrials.gov/ct2/show/NCT00388674.
  13. Hou JL, Jia JD, Wei L, et al. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China. J Viral Hepat 2013;20:811-820.
  14. Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008;52:598-605. https://doi.org/10.1128/AAC.01122-07
  15. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100. https://doi.org/10.1002/hep.24361
  16. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-182. https://doi.org/10.1016/j.jhep.2009.11.007
  17. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443-451. https://doi.org/10.1002/hep.24406
  18. Manns MP, Akarca US, Chang TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012;11:361-368. https://doi.org/10.1517/14740338.2012.653340
  19. Tenney DJ, Pokornowski KA, Rose RE, et al. 20 Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009;50(Suppl 1):S10.
  20. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514. https://doi.org/10.1002/hep.22841